Abstract
Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) is a novel semisynthetic vinca alkaloid with antitumor activity in non-small cell lung cancer. An oral preparation of this drug is under investigation and was tested in a multicenter phase II study in patients with stage IV measurable or evaluable non-small cell lung cancer. The initial vinorelbine dose was 100 mg/m2/wk (80 mg/m2/wk for patients with prior radiotherapy). Following an initial 37% incidence of grade 3 or 4 neutropenia, the dose was reduced by 40 mg/dose. Nausea, vomiting, diarrhea, and mucositis were other frequently observed toxicities. A preliminary analysis indicated a response rate of 14%, suggesting activity of this drug when administered orally.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Aged, 80 and over
-
Agranulocytosis / chemically induced
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Capsules
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Cohort Studies
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Neutropenia / chemically induced
-
Quality of Life
-
Remission Induction
-
Survival Rate
-
Vinblastine / administration & dosage
-
Vinblastine / adverse effects
-
Vinblastine / analogs & derivatives*
-
Vinblastine / therapeutic use
-
Vinorelbine
Substances
-
Antineoplastic Agents
-
Capsules
-
Vinblastine
-
Vinorelbine